Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Common Equity (2016 - 2025)

ENDRA Life Sciences has reported Common Equity over the past 6 years, most recently at $10.8 million for Q4 2021.

  • Quarterly Common Equity rose 50.42% to $10.8 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Dec 2021, up 50.42% year-over-year, with the annual reading at $10.8 million for FY2021, 50.42% up from the prior year.
  • Common Equity was $10.8 million for Q4 2021 at ENDRA Life Sciences, down from $13.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $17.9 million in Q1 2021 and troughed at -$1.4 million in Q1 2017.
  • The 5-year median for Common Equity is $4.3 million (2019), against an average of $5.6 million.
  • Year-over-year, Common Equity plummeted 106.38% in 2018 and then surged 1434.47% in 2021.
  • A 5-year view of Common Equity shows it stood at $5.3 million in 2017, then increased by 18.44% to $6.2 million in 2018, then decreased by 23.81% to $4.8 million in 2019, then surged by 50.59% to $7.2 million in 2020, then soared by 50.42% to $10.8 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Common Equity are $10.8 million (Q4 2021), $13.2 million (Q3 2021), and $15.0 million (Q2 2021).